Skip to main content

21.03.2024 | Viewpoint

The Quest to Revise the Uniform Determination of Death Act: Why We Tried, Why We Failed, and Where We Go from Here

verfasst von: Ariane Lewis

Erschienen in: Neurocritical Care

Einloggen, um Zugang zu erhalten

Excerpt

The Uniform Determination of Death Act (UDDA) was written in 1981 to identify the two ways to declare death: death by circulatory-respiratory criteria (DCRC) or brain death/death by neurologic criteria (BD/DNC) [1]. It states, “An individual who has sustained either (1) irreversible cessation of circulatory and respiratory functions, or (2) irreversible cessation of all functions of the entire brain, including the brainstem, is dead. A determination of death must be made in accordance with accepted medical standards.” Because of the concerns of multidisciplinary experts about the UDDA’s shortcomings, after colleagues with expertise in health law and clinical ethics and I (a neurointensivist) advocated that the Uniform Law Commission (ULC) should revise the UDDA, they empaneled a drafting committee to revise the UDDA in 2021 [2, 3]. I served as an observer on the drafting committee and provided expertise to help guide the discussion. In September 2023, the chair of the drafting committee announced that based on discussion with ULC leadership, work on the UDDA revision was being paused, with the plan to consider resumption in the future only if a revision that can be widely enacted seems feasible [4]. It is important for the neurocritical care community to understand the controversies associated with the content of the UDDA relative to BD/DNC determination, particularly in light of the recent publication of the 2023 BD/DNC guidelines by the American Academy of Neurology (AAN), American Academy of Pediatrics (AAP), Child Neurology Society (CNS), and Society of Critical Care Medicine (SCCM) [5]. In this article, I review why we tried to facilitate revision of the UDDA, why we failed, and where we go from here. …
Literatur
1.
Zurück zum Zitat President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Defining death: medical, legal and ethical issues in the determination of death, Washington D.C.; 1981. President’s Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research. Defining death: medical, legal and ethical issues in the determination of death, Washington D.C.; 1981.
2.
Zurück zum Zitat Lewis A, Bonnie RJ, Pope T, Epstein LG, Greer DM, Kirschen MP, et al. Determination of death by neurologic criteria in the United States: the case for revising the uniform determination of death act. J Law Med Ethics. 2019;47:9–24.CrossRefPubMed Lewis A, Bonnie RJ, Pope T, Epstein LG, Greer DM, Kirschen MP, et al. Determination of death by neurologic criteria in the United States: the case for revising the uniform determination of death act. J Law Med Ethics. 2019;47:9–24.CrossRefPubMed
3.
Zurück zum Zitat Lewis A. The uniform determination of death act is being revised. Neurocrit Care. 2022;36:335–8.CrossRefPubMed Lewis A. The uniform determination of death act is being revised. Neurocrit Care. 2022;36:335–8.CrossRefPubMed
5.
Zurück zum Zitat Greer DM, Kirschen MP, Lewis A, Gronseth G, Rae-Grant A, Ashwal S, et al. Pediatric and adult brain death/death by neurologic criteria consensus practice guideline. Neurology. 2023;101:1112–32.CrossRefPubMed Greer DM, Kirschen MP, Lewis A, Gronseth G, Rae-Grant A, Ashwal S, et al. Pediatric and adult brain death/death by neurologic criteria consensus practice guideline. Neurology. 2023;101:1112–32.CrossRefPubMed
6.
Zurück zum Zitat Bernat JL. Challenges to brain death in revising the uniform determination of death act: the UDDA revision series. Neurology. 2023;101:30–7.CrossRefPubMed Bernat JL. Challenges to brain death in revising the uniform determination of death act: the UDDA revision series. Neurology. 2023;101:30–7.CrossRefPubMed
7.
Zurück zum Zitat Greer D. Should the brain death exam with apnea test require surrogate informed consent? No: UDDA revision series. Neurology. 2023;101:221–2.CrossRefPubMed Greer D. Should the brain death exam with apnea test require surrogate informed consent? No: UDDA revision series. Neurology. 2023;101:221–2.CrossRefPubMed
8.
Zurück zum Zitat Berkowitz ID, Garrett J. Should the brain death exam with apnea test require surrogate informed consent? Yes: the UDDA revision series. Neurology. 2023;101:218–20.CrossRefPubMed Berkowitz ID, Garrett J. Should the brain death exam with apnea test require surrogate informed consent? Yes: the UDDA revision series. Neurology. 2023;101:218–20.CrossRefPubMed
9.
Zurück zum Zitat Lewis A, Kirschen MP. Potential threats and impediments to the clinical practice of brain death determination: the UDDA revision series. Neurology. 2023;101:270–9.CrossRefPubMed Lewis A, Kirschen MP. Potential threats and impediments to the clinical practice of brain death determination: the UDDA revision series. Neurology. 2023;101:270–9.CrossRefPubMed
10.
Zurück zum Zitat Joffe AR. Should the criterion for brain death require irreversible or permanent cessation of function? Irreversible: the UDDA revision series. Neurology. 2023;101:181–3.CrossRefPubMed Joffe AR. Should the criterion for brain death require irreversible or permanent cessation of function? Irreversible: the UDDA revision series. Neurology. 2023;101:181–3.CrossRefPubMed
11.
Zurück zum Zitat Rubin M. What is the ideal brain criterion of death: non clinical considerations: UDDA revision series. Neurology. 2023;101:86–7.CrossRefPubMed Rubin M. What is the ideal brain criterion of death: non clinical considerations: UDDA revision series. Neurology. 2023;101:86–7.CrossRefPubMed
12.
Zurück zum Zitat Nair-Collins M. Must hypothalamic neurosecretory function cease for brain death determination? Yes: the UDDA revision series. Neurology. 2023;101:134–6.CrossRefPubMed Nair-Collins M. Must hypothalamic neurosecretory function cease for brain death determination? Yes: the UDDA revision series. Neurology. 2023;101:134–6.CrossRefPubMed
13.
Zurück zum Zitat Varelas PN. Must hypothalamic neurosecretory function cease for brain death determination? No: the UDDA revision series. Neurology. 2023;101:137–9.CrossRefPubMed Varelas PN. Must hypothalamic neurosecretory function cease for brain death determination? No: the UDDA revision series. Neurology. 2023;101:137–9.CrossRefPubMed
14.
Zurück zum Zitat McGee A, Gardiner D. Should the criterion for brain death require irreversible or permanent cessation of function? Permanent: the UDDA revision series. Neurology. 2023;101:184–6.CrossRefPubMed McGee A, Gardiner D. Should the criterion for brain death require irreversible or permanent cessation of function? Permanent: the UDDA revision series. Neurology. 2023;101:184–6.CrossRefPubMed
15.
Zurück zum Zitat Lewis A. Should the revised uniform determination of death act address objections to the use of neurologic criteria to declare death? Neurocrit Care. 2022;37:377–85.CrossRefPubMed Lewis A. Should the revised uniform determination of death act address objections to the use of neurologic criteria to declare death? Neurocrit Care. 2022;37:377–85.CrossRefPubMed
16.
Zurück zum Zitat National Conference of Commissioners on Uniform State Laws. Annual meeting commission whole session report from draft commission to revise uniform determination death act, Honolulu, Hawaii; 2023. National Conference of Commissioners on Uniform State Laws. Annual meeting commission whole session report from draft commission to revise uniform determination death act, Honolulu, Hawaii; 2023.
17.
Zurück zum Zitat Thumma SA, Weeks E, Farahany NA. By statute or by common law? The legal determination of death. Am J Bioeth. 2024;24:1–2.CrossRefPubMed Thumma SA, Weeks E, Farahany NA. By statute or by common law? The legal determination of death. Am J Bioeth. 2024;24:1–2.CrossRefPubMed
18.
Zurück zum Zitat Pope TM. Time for federal standards on death determination: the national determination of death act. Am J Bioeth. 2024;24:111–3.CrossRefPubMed Pope TM. Time for federal standards on death determination: the national determination of death act. Am J Bioeth. 2024;24:111–3.CrossRefPubMed
19.
Zurück zum Zitat Finneran M, Lewis A. Engagement of a state medical society to promote uniform hospital policies on determination of brain death. Neurohospitalist. 2023;13:283–4.CrossRefPubMed Finneran M, Lewis A. Engagement of a state medical society to promote uniform hospital policies on determination of brain death. Neurohospitalist. 2023;13:283–4.CrossRefPubMed
Metadaten
Titel
The Quest to Revise the Uniform Determination of Death Act: Why We Tried, Why We Failed, and Where We Go from Here
verfasst von
Ariane Lewis
Publikationsdatum
21.03.2024
Verlag
Springer US
Erschienen in
Neurocritical Care
Print ISSN: 1541-6933
Elektronische ISSN: 1556-0961
DOI
https://doi.org/10.1007/s12028-024-01964-w

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.